文献速递神经肿瘤

血清蛋白质组与自身抗体多组学整合揭示胶质瘤诊断与预后生物标志物

Multiomics integration of serum proteome and autoantibody profiles reveals diagnostic and prognostic biomarkers in glioma.
PubMed 文献 · J Neurooncol · 2026-02-17

该研究对30例胶质瘤患者和30例匹配健康对照的血清进行TMT定量蛋白质组学,并在发现队列(55例胶质瘤、30例健康对照)和验证队列(32例胶质瘤、29例健康对照)中用定制肽微阵列检测IgG/IgM自身抗体。三种IgM组合(抗p-APOE-1、抗p-P53-1和抗p-SAA4-1)在发现集AUC为0.96、验证集为0.80;IgM-p-SAA4-1阳性是全胶质瘤患者更长生存的独立保护因素(P=0.010)。

要点

  • 三种IgM自身抗体组合对全胶质瘤诊断具有较高准确性(发现集AUC=0.96,验证集AUC=0.80)。
  • IgM-p-SAA4-1阳性与全胶质瘤患者更长生存独立相关(P=0.010)。
  • GBM IDH野生型亚组中IgG-p-P53-1和IgM-p-P53-1在训练集和验证集均显著高表达(P<0.05)。

核心结论

  • 整合蛋白质组与自身抗体谱识别并验证了具有稳健全胶质瘤诊断准确性和预后相关性的血清IgM组合。
  • 三种IgM组合显示全胶质瘤诊断价值,而GBM IDH野生型亚型特异性生物标志物需扩大样本量进一步验证。

研究设计与样本

  • 对30例胶质瘤患者和30例匹配健康对照的血清进行TMT定量蛋白质组学以识别差异表达蛋白。
  • 用候选肿瘤相关抗原设计定制肽微阵列,在发现队列(55例胶质瘤、30例健康对照)和验证队列(32例胶质瘤、29例健康对照)中评估IgG/IgM自身抗体。
  • 通过Kaplan–Meier和Cox回归分析预后价值,并结合TCGA转录组学和单细胞RNA测序数据。
  • 对GBM IDH野生型队列按IDH状态进行亚组分析以验证亚型特异性生物标志物潜力。

主要发现

  • 蛋白质组学鉴定出877种蛋白质,差异表达蛋白富集于细胞外基质重塑、补体/凝血级联和代谢/氧化应激通路。
  • 三种IgM组合(抗p-APOE-1、抗p-P53-1和抗p-SAA4-1)显示高诊断性能(AUC=0.96;验证集0.80)。
  • GBM IDH野生型亚组中IgG-p-P53-1和IgM-p-P53-1在训练集和验证集均显著高表达(P<0.05)。
  • IgM-p-APOE-1在训练集显示中等诊断效力(AUC=0.776),但在验证集泛化性差(AUC=0.483)。
  • IgM-p-SAA4-1阳性是全胶质瘤患者更长生存的独立保护因素(P=0.010)。

关键数值与推荐

  • 三种IgM组合诊断全胶质瘤的AUC在发现集为0.96、验证集为0.80。
  • IgM-p-APOE-1在训练集AUC=0.776,验证集AUC=0.483。
  • IgM-p-SAA4-1阳性与全胶质瘤患者更长生存独立相关(P=0.010)。
  • GBM IDH野生型亚组中IgG-p-P53-1和IgM-p-P53-1在训练集和验证集均显著高表达(P<0.05)。

临床怎么用

  • 三种IgM自身抗体组合可作为全胶质瘤无创诊断的候选血清标志物。
  • IgM-p-SAA4-1阳性状态可能有助于全胶质瘤患者的预后分层。
  • GBM IDH野生型亚型特异性标志物目前证据有限,需扩大样本验证后考虑临床应用。

局限性

  • GBM IDH野生型亚型特异性生物标志物需扩大样本量进一步验证。
  • IgM-p-APOE-1在验证集泛化性差(AUC=0.483)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioma is the most aggressive primary brain tumor with glioblastoma (GBM, IDH-wildtype) as its most malignant subtype, and is associated with a dismal prognosis, creating an urgent need for noninvasive biomarkers to enable early detection and prognostic stratification. Single-marker detection exhibits inherent limitations in clinical practice, whereas multi-marker panels hold greater promise for enhancing diagnostic efficacy. METHODS: Tandem mass tag (TMT)-based quantitative proteomics was performed on sera from 30 glioma patients and 30 matched healthy controls (HCs) to identify differentially expressed proteins (DEPs). Candidate tumor-associated antigens were used to design a custom peptide microarray assessing IgG/IgM autoantibodies in the discovery (n = 55 glioma patients, 30 HCs) and validation (n = 32 glioma patients, 29 HCs) cohorts. Prognostic value was analyzed via Kaplan–Meier and Cox regression, and findings were integrated with TCGA transcriptomics and single-cell RNA sequencing data to determine immune associations and cellular origins. Subgroup analysis by IDH status was performed for GBM IDH-wildtype cohort to verify subtype-specific biomarker potential. RESULTS: Proteomics identified 877 proteins, with DEPs enriched in extracellular matrix remodeling, complement/coagulation cascades, and metabolism/oxidative stress pathways. A three-IgM panel (anti-p-APOE-1, anti-p-P53-1, and anti-p-SAA4-1) showed high diagnostic performance (AUC = 0.96; 0.80 validation). In the GBM IDH-wildtype subgroup, IgG-p-P53-1 and IgM-p-P53-1 were significantly highly expressed in the training set and validation set (P < 0.05), while IgM-p-APOE-1 showed moderate diagnostic efficacy in the training set (AUC = 0.776) but poor generalization in the validation set (AUC = 0.483). IgM-p-SAA4-1 positivity was an independent protective factor for longer survival in pan-glioma patients(P = 0.010). APOE and IL1B are expressed predominantly by tumor-associated macrophages, with divergent prognostic implications at the transcript level. CONCLUSION: Integrated proteomic–autoantibody profiling identified and validated a serum IgM panel with robust pan-glioma diagnostic accuracy and prognostic relevance in glioma. The three-IgM panel shows pan-glioma diagnostic value, while GBM IDH-wildtype subtype-specific biomarkers require further verification with expanded sample size. These biomarkers reflect interactions between humoral immunity, tumor gene expression, and the immune microenvironment, supporting their potential for clinical translation in glioma early detection and personalized patient stratification.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Meng W, Duan J, Guo C, et al. Multiomics integration of serum proteome and autoantibody profiles reveals diagnostic and prognostic biomarkers in glioma. J Neurooncol. 2026. PMID: 41701384. doi:10.1007/s11060-025-05410-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。